Monitoring of anticoagulants of secondary haemostasis;Monitoring von antikoagulanzien der sekundären hämostase

Hamostaseologie

Volumn 29, Issue 3, 2009, Pages 268-273

  Schuster, Bernhard ^a  

^a Haemochrom Diagnostica GmbH   (Germany)

Author keywords

Chromogenic methods; Direct factor Xa inhibitors; Direct thrombin inhibitors; New anticoagulants; Routine monitoring

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DANAPAROID; DESULFATOHIRUDIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BLOOD CLOTTING TEST; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MONITORING; HEMOSTASIS; HUMAN; IN VIVO STUDY; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; PRACTICE GUIDELINE; REVIEW; VEIN THROMBOSIS;

EID: 68649119622     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617042     Document Type: Review

References (57)

1. Ahmad S, Iqbal O, Ahsan A et al. Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods. Int Angiol 1999; 18: 198-205. (Pubitemid 30040641)
2. Alban S. Pharmakologie der Heparine und der direkten Antikoagulanzien. Hämostaseologie 2008; 28: 400-420.
3. Bara L, Combe Tanzali S, Conard J et al. Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest). Haemostasis 1987; 17: 127-133.
4. Bergström K, Egberg N. Determination of vitamin K sensitive coagulation factors in plasma. Studies on three methods using synthetic chromogenic substrates. Thromb Res 1976; 12: 531-547.
5. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2: 551-554. (Pubitemid 40185676)
6. Brill-Edward P, Ginsberg JS, Johnston M et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-109. (Pubitemid 23286474)
7. Calatzis A, Spannagl M, Gempeler-Messina P et al. The prothrombinase-induced clotting test: A new technique for the monitoring of anticoagulants. Haemostasis 2000; 30 (suppl 2): 172-174. (Pubitemid 32234159)
8. Calatzis A, Peetz D et al. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 2008; 130: 446-454.
9. Choay J, Petitou M, Lormeau JC et al. Structure activity relationship in heparin: a synthetic penta - saccharid with high affinity for antithrombin III and elicity high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 111: 442-449.
10. Conley, CL, Hartmann RC, Lalley JS. The relationship of heparin activity to platelet concentration. Proc Soc Exp Biol Med 1948; 68: 284-287.
11. Contant G, Gouault-Heilmann M, Martinoli Jl: Heparin inactivation during blood storage: Its prevention by blood collection in citric acid, theophylline, adenosine, dipyramidole-CTAD mixture Thromb Res 1983; 31: 365-374.
12. Crowther M, Berry LR, Monagle PT, Chan AKC. Mechanism responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002; 116: 178-186. (Pubitemid 34122079)
13. Dawes J, Pumphrey CW, McLaren KM et al. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982; 27: 65-76. (Pubitemid 12061757)
14. Dämgen-von Brevern G, Kläffling C, Lindhoff-Last E. Überwachung der Antikoagulanzientherapie mit Fondaparinux. Hämostaseologie 2005; 25: 281-285.
15. Depasse F, Gerotziafas GT, Busson J et al. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra®) anti Xa activity. J Thromb Haemost 2004; 2: 346-379.
16. Erlanger BF, Kokowsky N, Cohen W. The preparation and properties of two chromogenic substrates of trypsin. Arch Biochem Biophys 1961; 95: 271-278.
17. Fenyvesi T, Jörg I, Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb 2002; 32: 174-179. (Pubitemid 37449310)
18. Friberger P, Krig E et al. Coacute Heparin: A new simple monotest for monitoring heparin treatment. Sem Thromb Haemost 1993; 19 (Suppl 1): 86-89. (Pubitemid 23192717)
19. Griesbach U, Stürzebecher J, Markwardt F. Assay of Hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 1985; 37: 347-350. (Pubitemid 15163068)
20. Groetch H, Damm D, Ben Youssef R et al. Comparison of two different methods for the determination of rDNA Hirudin in plasma samples: HPLC vs. a chromogenic thrombin substrate. Thromb Res 1991; 64: 273-277.
21. Hafner G, Fickenscher K, Friesen HJ et al. Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma. Thromb Res 1995; 77: 165-173.
22. Hafner G, Roser M, Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Throm Hemost 2002; 28: 425-430. (Pubitemid 35217487)
23. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 2008; 123: 396-403.
24. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost 2004; 2: 547-550. (Pubitemid 40185675)
25. Hirsh J, Warkentin TE, Raschke R et al. Heparin and low-molecular-weight heparin. Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998; 114: 4895-5105.
26. Iorio A. Prevention of venous thromboembolism after major orthopaedic surgery summing up evidence about old and new antithrombotic agents. J Thromb Haemost 2004; 2: 1055-1057. (Pubitemid 40186076)
27. Iyer L, Adam M, Amiral J et al. Development and validation of two enzyme-linked immunosorbent assay (ELISA) methods for recombinant hirudin. Semin Thromb Hemost 1995; 21: 184-192.
28. Kathiresan S, Shiomura J, Lang I-K. Argatroban. J Thromb Thrombol 2002; 13: 41-47.
29. Kemkes-Matthes B. Orale Antikoagulanzien vom Cumarintyp. Hämostaseologie 2008; 28: 421-427.
30. Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: Inter-assay variability. Thromb Haemost 1999; 82: 1289-1293. (Pubitemid 29473794)
31. Kläffling C, Piechottka G et al. Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium. The Drug Monit 2006; 28: 375-381. (Pubitemid 44314925)
32. Kler A, Samama MM. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprohylaxis, an alternative to vitamin K antagonists. J Thromb Haemost 2005; 3: 473-481.
33. Lange U, Olschewski A, Nowak G, Bucha E. Ecarin Chromogenic Assay. Hämostaseologie 2005; 25: 293-300.
34. Larsson M, Logren U, Ahnhoff M et al. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 47-55. (Pubitemid 34142375)
35. Levi M. All heparins are equal, but some are more equal than others. J Thromb Haemost 2003; 1: 884-885.
36. Lindahl U, Hook M, Glycosaminoglucanes and their binding to biological macromolecules. Ann Rev Biochem 1978; 47: 385-414.
37. Lüpke U, Marx A, Teßmann R, Lindhoff-Last E. Danaparoid (Orgaran) zur Antikoagulation bei der maschinellen Autotransfusion mit Cell Saver 5 (Haemonetics). Anaesthesist 2001; 50: 26-31.
38. Lyon SG, Lasser EC, Stein R. Modification of an amidolytic heparin assay to express protein-bound heparin and to correct for the effect of antithrombin III concentration. Thromb Haemost 1987; 58: 884-887. (Pubitemid 18020456)
39. N.N. Low Molecular weight Heparins. European Pharmacopoeia 5.5 2004; No.2318.
40. N.N. Danaparoid Sodium. European Pharmacopoeia 5.5 2006; No. 07/2006:2090.
41. Mazoyer E, Drouet L, Delahousse B et al. Activated partial thromboplastin time is more sensitive than ecarin clotting time for monitoring low doses of lepirudin. Thromb Res 2002; 106: 271-272. (Pubitemid 35248064)
42. McKay EJ, Laurell CB. The interaction of heparin with plasma proteins. J Lab Clin Med 1980; 95: 69-80.
43. Molitor B, Klingel R, Hafner G. Überwachung der Heparintherapie bei Akutdialysen. Hämostaseologie 2005; 25: 272-278.
44. Mouton C, Calderon J, Janvier G et al. Dextrane sulphate included in factor Xa assay reagent over-estimates heparin activity in patients after reversal by protamine. Thromb Res 2003; 111: 273-279. (Pubitemid 38021947)
45. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996; 22: 197-202. (Pubitemid 26239913)
46. Nowak G. Monitoring of the action of antithrombin agents by ecarin clotting time. In: Pifarre R (ed). New Anticoagulants for the Cardiovascular Patient. Hanley & Belfus: Philadelphia 1997: 539-550.
47. Nowak G. Clinical monitoring of hirudin and direct thrombin inhibitors. Sem Thromb Hemost 2001; 27: 537-541. (Pubitemid 32989380)
48. Paolucci F, Frasa H, van Aarle F et al. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra®) in human plasma and other biological matrices. Clin Lab 2003; 49: 451-460. (Pubitemid 37266109)
49. Pötzsch B, Hund S, Madlener K, et al. Monitoring of recombinant hirudin assessment of a plasma based ecarin clotting time assay. Thromb Res 1997; 86: 373-383. (Pubitemid 27305589)
50. Reed SV, Haddon ME, Denson KW. An attempt to standardize the aPTT for heparin monitoring, using the P.T ISI/INR system of calibration: results of a 13 centre study. Thromb Res 1994; 74: 515-522. (Pubitemid 24173333)
51. Rosén S, Casoni MC. Heparin therapy and monitoring: A role for the chromogenic antifactor Xa assay. Am Clin Lab 2001; 8: 35-37.
52. Rosén S. Chromogenic methods in coagulation diagnostics. Hämostaseologie 2005; 25: 259-266.
53. Teien AM, Abilgaard U, Lie M. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416.
54. Teien A, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410. (Pubitemid 8061566)
55. Ten Cate H, Lamping RJ, Henry P et al. Automated amidolytic method for determining heparin, a heparinoid, and a low Mr Heparin fragment, based on their anti Xa activity. Clin Chem 1984; 30: 860-864.
56. Walenga JM, Hoppenstedt D, Kota M et al. Laboratory assays for the evaluation of recombinant hirudin. Haemostasis 1991; 21: 49-63.
57. Young E, Cosmi B, Weizu J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625-1330 (Pubitemid 23310568)